DIA

@DrugInfoAssn

DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate health care product development. Get started by joining our email list.

Global
Vrijeme pridruživanja: travanj 2009.

Tweetovi

Blokirali ste korisnika/cu @DrugInfoAssn

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrugInfoAssn

  1. prije 9 sati

    What lessons can be learned from PerfO assessments, and how can this help establish content validity in patient-reported outcome measurement in clinical trials? Let’s talk about meaningfulness of technology-driven measures!

    Poništi
  2. prije 14 sati

    [Sponsored] Running clinical trials is expensive! Speed up the process by using AI technology to intelligently automate the analysis of clinical data Ready to see Arria in action? Request a demo now!

    Poništi
  3. prije 15 sati

    If you work in Pharmacovigilance, explore our partnership with the Chair, the Dutch Medicines Evaluation Board! Join our Content Preview Webinar on 13 February 9AM CET to ask questions and learn about the most comprehensive PV Course in Europe!

    Poništi
  4. 4. velj

    In six days, Ashley Brown will share her story. Join DIA at for "A New Passion to Life: Experiencing the Impact of Regulatory Submissions". You'll be glad you did!

    Poništi
  5. 4. velj

    [Sponsored] Adis Pharmacovigilance is the expert solution for regulatory literature monitoring, from the industry-leading provider of drug safety and pharmacovigilance content. Find out more on how Adis can partner with you here:

    Poništi
  6. 4. velj

    Starting in 30 minutes! Gain insight into FDA's final guidance on Adaptive Design for Drugs and !

    Poništi
  7. 4. velj

    This March 17 in Brussels, the DIAmond Session on Shortages will see the EU Commission, Regulators, NGOs & Industry experts debate drug shortages, exploring causes & solutions! Session chairs Kristin Raudsepp & Thomas Senderovitz await you at DIA Europe:

    Poništi
  8. 3. velj

    How do regional trends in differ? Get prepared and understand present audit expectations of authorities! In just one hour, you'll review recent audit observations and discuss best preparation practices.

    Poništi
  9. 3. velj

    Meet leading regulators and industry experts in London at the Pharmacovigilance Strategies Workshop, which provides guidance and practical recommendations to adopt to the changing Pharmacovigilance landscape in Europe. Early Bird Rates end February 11!

    Poništi
  10. 2. velj

    Novel coronavirus originating in China has already spread to several continents, raising global fear of cases emerging in more countries. Where can you learn more about global disease outbreaks?

    Poništi
  11. 31. sij

    Get involved in by submitting a poster abstract during our Call for Professional & Student Posters! This is you opportunity to get your research, best practices, and lessons learned in front of the right audience. The deadline is Feb 13!

    Poništi
  12. 31. sij

    Get an overview of recent regulatory efforts in the area of Complex Innovative Trial Designs, including insight into FDA's final guidance on Adaptive Design for Drugs and ! What can you learn in one hour?

    Poništi
  13. 31. sij

    This course will explore how RWE can be harnessed to measure outcomes & better understand the price, value, and impact of next generation therapies. Join us to discuss creative pricing solutions towards improving patient access to new treatment classes:

    Poništi
  14. 31. sij

    Novel coronavirus originating in China has already spread to several continents, raising global fear of cases emerging in more countries. Where can you learn more about global disease outbreaks?

    Poništi
  15. 30. sij

    Coming to in Miami: Regulators and industry professionals from 12 American nations, the EU, and...you? Advance rates end tonight, 1/30!

    Poništi
  16. 30. sij

    [Sponsored] Live at 11 AM! Join CitiusTech and DIA for a look at data management and compliance challenges w/varying State Drug Price Transparency Laws & approaches for manufacturers to effectively & efficiently manage complex reporting processes.

    Poništi
  17. 30. sij

    FDA's Patient-Focused Drug Development (PFDD) Guidances will impact Marketing Strategies for . What are they and where can you learn more? Click to view!

    Poništi
  18. 30. sij

    How are Pharmaceutical & reimbursement policies developing? How is the use of HTA evolving? Companies should address recent developments by reinforcing their market access capabilities. This Training Course is a great place to get started:

    Poništi
  19. proslijedio/la je Tweet
    29. sij

    Howard Chazin, OGD, FDA, shares proactive safety surveillance of complex generic drug-device combo prods at .

    Poništi
  20. 29. sij

    Join Gautam Gulati, MD, for 3 meetings in 1! The DIA Medical Affairs and Scientific Communications Forum features crosscutting plenary sessions and , medical writing, and MSL tracks. Follow one or create your own! Early Bird Rates end 1/30!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·